Notice: Essential maintenance to our website is being carried out this weekend 22nd-23rd January so you may experience some disruption in accessing the site.
This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: sodium-glucose co-transporter 2 (SGLT2) inhibitor

January 2022 Br J Cardiol 2022;29(1) doi:10.5837/bjc.2022.002

Foundational drugs for HFrEF: the growing evidence for a rapid sequencing strategy

Kieran F Docherty, John J V McMurray

Abstract

Introduction To date, five pharmacological approaches have been demonstrated to significantly reduce the risk of mortality and prevent hospitalisation for worsening heart failure (HF) in patients with HF with reduced ejection fraction (HFrEF): the combination of a neprilysin inhibitor and an angiotensin-receptor blocker (i.e. sacubitril/valsartan), a beta blocker, a mineralocorticoid-receptor antagonist (MRA) and a sodium-glucose co-transporter 2 (SGLT2) inhibitor. Hereafter, these five agents, which can be prescribed as four pills, will be referred to as the ‘four foundational therapies for HFrEF’.1-11 The combination of these four ther

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now